Welcome to Greehey Children's Cancer Research Institute
Clinical mission: Greehey CCRI does not participate directly in patient care, but interacts with members of the Division of Pediatric Hematology-Oncology to provide support for clinical research, banking of clinical specimens and annotation of such specimens to facilitate patient-oriented research. In addition, as our research mission includes performing research that translates into clinical care, the Greehey CCRI supports infrastructure for human subjects’ research and investigator-initiated trials in pediatric cancer. Since much of research in pediatric cancer includes participation in cooperative group trials, Greehey CCRI supports the involvement of investigators in Children’s Oncology Group participation. This year the UT Health Cancer Center has become a member of The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). POETIC's pediatric oncology studies focus on the biologic basis for anti-cancer therapy, and in particular, attempt to explore and evaluate new agents and novel combinations of therapies early in clinical development.
Research Mission: Greehey CCRI’s research mission is to advance scientific knowledge relevant to childhood cancer, to contribute to the understanding of causes of childhood cancer, and to accelerate the translation of knowledge into novel therapies. Through discovery, development, and dissemination of new scientific knowledge, Greehey CCRI strives to have a national and global impact on the problem of childhood cancer. Areas of research that have been our strength have included cancer genomics and microRNA biology. We are developing expertise in drug delivery, with a focus on nano-technology driven delivery of microRNA mimics and antagomiRs, which will be further developed in the coming year. With recruitment of the new director, our focus on developmental therapeutics will increase dramatically in the next few years. The Pediatric Translational Working Group formed last year under the guidelines of the UT Health Cancer Center P30 format now meets regularly. The purpose of this group is to coordinate discoveries with application to development of novel therapies.